Clinical trials: Brain Necrosis
Infarction, Middle Cerebral Artery, Middle Cerebral Artery Stroke
Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke
The purpose of this randomized, double-blind, placebo-controlled multicenter study is to determine in a cohort of 506 patients with acute ischemic stroke in the middle cerebral artery territory, the effect of a three-day…
- Conditions
- Infarction, Middle Cerebral Artery, Middle Cerebral Artery Stroke, Stroke, Acute
- Trial name
- ESS (NCT00604630)
- Testing
- recombinant human erythropoietin alfa, 0.9% NaCl
- Where
- 9 sites in Germany
- Volunteers
- 522 people
- Sponsor
- Max-Planck-Institute of Experimental Medicine
Socioeconomic Status, Secondary Prevention
Socioeconomic Status, Secondary Prevention Activities and Recurrence After a Myocardial Infarction
This is a nationwide cohort study on real-world patients (n≈30,000) surviving a first myocardial infarction (MI) 2006-2013 and alive to attend a routine 1-year follow-up.
- Conditions
- Socioeconomic Status, Secondary Prevention, Myocardial Infarction, Cardiovascular Disease
- Trial name
- NCT04199663
- Volunteers
- 30,191 people
- Sponsor
- Karolinska Institutet
Stroke, Acute, Cerebrovascular Disorders
Therapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion
This multicenter registry study, which record the therapy strategy and follows up these acute ischemic stroke (AIS) patients with low NIHSS and large vessel occlusion (LVO), is intended to provide the important data for therapy…
- Conditions
- Stroke, Acute, Cerebrovascular Disorders, Brain Diseases, Central Nervous System Diseases
- Trial name
- TEMPOS (NCT06633809)
- Testing
- Immediate endovascular therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sir Run Run Shaw Hospital
Stroke, Myocardial Infarction
Insulin Resistance Intervention After Stroke Trial
The purpose of this study is to determine if pioglitazone is effective in preventing future strokes or heart attacks among non-diabetic persons who have had a recent ischemic stroke.
- Conditions
- Stroke, Myocardial Infarction, Diabetes
- Trial name
- IRIS (NCT00091949)
- Testing
- pioglitazone
- Where
- 183 sites in United States, Australia and 6 more
- Volunteers
- 3,876 people
- Sponsor
- Yale University
Branch Atheromatous Disease, Acute Ischemic Stroke
Early Identification and Diagnosis of BAD-related Stroke
Branch atheromatous disease (BAD)-related stroke is an important subtype of acute ischemic stroke involving penetrating arteries and is associated with early neurological deterioration.
- Conditions
- Branch Atheromatous Disease, Acute Ischemic Stroke, Cerebral Infarction
- Trial name
- SMART-BAD (NCT07693816)
- Testing
- Multisource clinical-imaging artificial intelligence diagnostic assessment
- Where
- 11 sites in China
- Volunteers
- 1,602 people
- Sponsor
- Peking Union Medical College Hospital
Cerebral Infarction, Stenosis Artery
The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis
Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial.
- Trial name
- CHANGE (NCT06757764)
- Testing
- Aspirin, Clopidogrel, Cilostazol
- Where
- 24 sites in South Korea
- Volunteers
- 2,340 people
- Sponsor
- Asan Medical Center
Locked-in Syndrome, Neuromuscular Diseases
Investigation on the Cortical Communication System
The goal of this clinical trial is to demonstrate communication through a brain implant in people in locked-in state, i.e. people with severe paralysis and communication problems.
- Conditions
- Locked-in Syndrome, Neuromuscular Diseases, Brainstem Stroke, Traumatic Brain Injury
- Trial name
- CortiCom (NCT06207591)
- Testing
- ECoG (electrocorticography) sensing
- Where
- Netherlands
- Volunteers
- 2 people
- Sponsor
- UMC Utrecht
Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease
Prognosis of Cerebral Small Vessel Disease
Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation. The aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients…
- Conditions
- Cerebral Amyloid Angiopathy, Small Vessel Cerebrovascular Disease, Cadasil, CAA - Cerebral Amyloid Angiopathy
- Trial name
- PRO-SVD (NCT05734378)
- Where
- Switzerland
- Volunteers
- 900 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Renal Replacement Therapy, Renal Dialysis
A Clinical Trial of IntensiVE Dialysis
This study will assess clinical outcomes of extended weekly hours of haemodialysis (>= 24 hours per week) compared with standard hours of haemodialysis (<=18 hours/week) in people with ESKD.
- Conditions
- Renal Replacement Therapy, Renal Dialysis, End Stage Kidney Disease, End Stage Renal Disease
- Trial name
- ACTIVE (NCT00649298)
- Testing
- haemodialysis
- Where
- 40 sites in Australia, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- The George Institute
Stroke, Cerebrovascular Disorders
Endovascular Treatment Beyond 24 Hours for Acute Ischemic Stroke Caused by Anterior Circulation Large Vessel Stenosis
Endovascular therapy (EVT) is currently recommended as the first-line treatment for patients with acute large vessel occlusion (LVO) in the anterior circulation within 24 hours of symptom onset.
- Conditions
- Stroke, Cerebrovascular Disorders, Brain Diseases, Nervous System Diseases
- Trial name
- EVT-BELATED (NCT06959199)
- Testing
- Endovascular Treatment, Best Medical Treatment
- Where
- China
- Volunteers
- 432 people
- Sponsor
- The Second Hospital of Anhui Medical University
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-2 (NCT01975389)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,595 sites in United States, Argentina and 33 more
- Volunteers
- 10,564 people
- Sponsor
- Pfizer
Cerebral Infarction
Study on Yangxue Nao Granules Reducing the Risk of Stroke
Objective: To explore the effectiveness of raising serum nao granules in reducing the risk of bleeding in patients with acute ischemic stroke treated with intravenous thrombolysis in the real world
- Trial name
- NCT04949906
- Testing
- Raise serum brain granules, No nourishing serum brain granules are used
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking University Third Hospital
Lacunar Stroke
The Relationship Between Controlling Risk Factors and Cerebral Haemodynamics in Lacunar Stroke
The goal of this observational study is to look at differences in brain blood flow before and after management of risk factors such as high blood pressure and diabetes in patients with lacunar stroke.
- Trial name
- LACUNAR_CA (NCT06354881)
- Testing
- Transcranial Doppler Ultrasonography (TCD) during sit-stand manoeuvres
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University of Leicester
Cerebral Infarction
Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
RATIONALE: Elevation in pulsatility indices (PIs), measured by transcranial Doppler (TCD), has been postulated to reflect downstream increased vascular resistance caused by small-vessel disease (SVD).
- Trial name
- ECLIPse (NCT00741286)
- Testing
- Aspirin, cilostazol
- Where
- 8 sites in South Korea
- Volunteers
- 203 people
- Sponsor
- Inje University
Myocardial Infarction, Angina Pectoris
Improving Intermediate Risk Management. MARK Study
Cardiovascular risk functions fail to identify more than 50% of patients who develop cardiovascular disease. This is especially evident in the intermediate-risk patients in which clinical management becomes difficult.
- Conditions
- Myocardial Infarction, Angina Pectoris, Stroke, Peripheral Arterial Disease
- Trial name
- MARK (NCT01428934)
- Where
- Spain
- Volunteers
- 2,495 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Cerebral Infarction, TIA
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
Anticoagulant treatment for non-valvular atrial fibrillation (AF) associated with cerebral infarction/ TIA is one of the recognized treatment of stroke prevention.
- Trial name
- ERSAF (NCT03749057)
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 400 people
- Sponsor
- General Hospital of Shenyang Military Region
Brain Infarction, Transient Ischemic Attack
Aortic Arch Related Cerebral Hazard Trial (ARCH)
The ARCH is a controlled trial with a sequential design and with a prospective, randomized, open-label, blinded-endpoint (PROBE) methodology.
- Conditions
- Brain Infarction, Transient Ischemic Attack, Embolism
- Trial name
- ARCH (NCT00235248)
- Testing
- Warfarin, Clopidogrel-aspirin
- Where
- 2 sites in Australia, France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Thrombosis, Atherothrombosis
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer
To date, the investigators have successfully employed a radiotracer (18F-sodium fluoride) as a marker of necrotic inflammation in human atherosclerosis.
- Conditions
- Thrombosis, Atherothrombosis, Myocardial Infarction, STEMI
- Trial name
- iThrombus (NCT03943966)
- Testing
- 18F-GP1 PET CT
- Where
- United Kingdom
- Volunteers
- 73 people
- Sponsor
- University of Edinburgh
Stroke, Transient Ischemic Attack
Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives
Stroke is one of the major causes not only of mortality, but of disease burden worldwide, because of residual disability and cognitive decline.
- Conditions
- Stroke, Transient Ischemic Attack, Hypertension
- Trial name
- ESH-CHL-SHOT (NCT01563731)
- Testing
- all approved antihypertensive drugs; all approved statins
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Istituto Auxologico Italiano